Status:
UNKNOWN
Platelet Reactivity After an Eastern Asian Loading Dose of Prasugrel in Taiwanese ACS Patients
Lead Sponsor:
Feng Yuan Hospital, Ministry of Health and Welfare
Collaborating Sponsors:
Cheng-Hsin General Hospital
Conditions:
Acute Coronary Syndrome
Hemorrhage
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Prasugrel has a faster onset of action and greater platelet inhibition with less inter-individual response variability than clopidogrel. Japan and Taiwan are the only two nations where adjusted/Asian ...
Detailed Description
Rationale and Background Prasugrel provides more potent and rapid platelet inhibition compared to Clopidogrel. Rapid and effective inhibition of the platelet P2Y12 receptor is of pivotal importance i...
Eligibility Criteria
Inclusion
- Age\>=20
- Mentally competent to provide an informed consent.
- A person being diagnosed with acute coronary syndrome and arranged for a percutaneous coronary intervention.
Exclusion
- A history of hemorrhagic stroke at any time in the past.
- Active internal bleeding or has a history of a bleeding disorder (i.e. hemophilia).
- Severe liver disease; for example, cirrhosis.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04768582
Start Date
May 1 2020
End Date
May 1 2021
Last Update
February 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Feng Yuan Hospital
Taichung, Taiwan, 42055